Merck cholesterol pill enlicitide and cancer therapy sac-TMT tapped for new priority program FDA expects Merck to submit applications in April and autumn of 2026, documents show Both drugs if approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback